Experience

Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong Stock Exchange. Zai Lab is the first company listed under both…

Davis Polk advised the representatives of the several underwriters in connection with the $1.3 billion initial public offering of 39,807,691 shares of Class A common stock of GoodRx…

Davis Polk advised the representatives of the initial purchasers in a Rule 144A offering by Omnicell, Inc. of $575 million aggregate principal amount of 0.25% convertible senior notes due…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,200,000 shares of common stock of…

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791,665 shares of common stock of Natera, Inc. for total gross…

Davis Polk advised MDLIVE Inc. in connection with its private placement of approximately $50 million in shares of its Series F preferred stock.MDLIVE offers virtual healthcare services to…

Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,500,000 new H shares for an aggregate consideration of approximately HK$1.2 billion (approximately US…

Davis Polk advised the lead placement agent in connection with I-Mab’s $418 million private placement of 29,133,502 ordinary shares and warrants to subscribe for 5,341,267 ordinary shares…

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…